Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Julie M. Lade"'
Autor:
Julie M. Lade, Manuella R. Andrade, Clark Undem, Jasmine Walker, Haiyang Jiang, Xin Yun, Larissa A. Shimoda
Publikováno v:
Frontiers in Physiology, Vol 14 (2023)
Exposure to hypoxia, due to high altitude or chronic lung disease, leads to structural changes in the pulmonary vascular wall, including hyperplasia and migration of pulmonary arterial smooth muscle cells (PASMCs). Previous studies showed that hypoxi
Externí odkaz:
https://doaj.org/article/c030ffc526554d998e6a2f5f314679ea
Autor:
Babak Basiri, Fang Xie, Bin Wu, Sara C. Humphreys, Julie M. Lade, Mai B. Thayer, Pam Yamaguchi, Monica Florio, Brooke M. Rock
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 21, Iss , Pp 725-736 (2020)
There has been a renewed interest in therapeutic small interfering RNAs (siRNAs) over the past few years. This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver. In genera
Externí odkaz:
https://doaj.org/article/31612adf3dbc4f6d9346df118252c413
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Abstract Oligonucleotide therapeutics use short interfering RNA (siRNA) or antisense oligonucleotide (ASO) molecules to exploit endogenous systems—neutralizing target RNA to prevent subsequent protein translation. While the potential clinical appli
Externí odkaz:
https://doaj.org/article/22cff2a3388640828a7f309b40b4cccd
Publikováno v:
EBioMedicine, Vol 2, Iss 9, Pp 1145-1152 (2015)
Tenofovir (TFV) is used in combination with other antiretroviral drugs for human immunodeficiency virus (HIV) treatment and prevention. TFV requires two phosphorylation steps to become pharmacologically active; however, the kinases that activate TFV
Externí odkaz:
https://doaj.org/article/d426955aa6904834a31112db99ef349f
Autor:
Sue Li, Jennifer Farrior, Paul G. Richardson, Linda-Gail Bekker, Herana Kamal Seneviratne, Shobha Swaminathan, Nyaradzo Mgodi, Joseph Tillotson, Jessica Justman, Namandjé N. Bumpus, Julie M. Lade, Nirupama Sista, Craig W. Hendrix, Subash Pathak
Publikováno v:
AIDS Res Hum Retroviruses
A long-acting injectable formulation of rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor, is currently under investigation for use in human immunodeficiency virus (HIV) maintenance therapy. We previously characterized RPV metabolis
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports
Scientific Reports
Oligonucleotide therapeutics use short interfering RNA (siRNA) or antisense oligonucleotide (ASO) molecules to exploit endogenous systems—neutralizing target RNA to prevent subsequent protein translation. While the potential clinical application is
Autor:
Mai B. Thayer, Brooke M. Rock, Jabbar Campbell, Sara C. Humphreys, Dan Adams, Wen Li Kelly Chen, Julie M. Lade
Publikováno v:
Journal of Medicinal Chemistry. 63:6407-6422
After two decades teetering at the intersection of laboratory tool and therapeutic reality, with two siRNA drugs now clinically approved, this modality has finally come into fruition. Consistent with other emerging modalities, initial proof-of-concep
Autor:
Sara C. Humphreys, Brooke M. Rock, Kelvin K. C. Sham, Richard Smith, Xin Huang, Bin Wu, Yue Hao, Babak Basiri, Mai B. Thayer, Julie M. Lade
Publikováno v:
Drug Metabolism and Disposition. 47:1174-1182
Understanding small interfering RNA (siRNA) fraction unbound (fu) in relevant physiologic compartments is critical for establishing pharmacokinetic-pharmacodynamic relationships for this emerging modality. In our attempts to isolate the equilibrium f
Publikováno v:
Drug Metabolism and Disposition. 47:419-423
It is well recognized that nonspecific binding of a drug within an in vitro assay (fu) can have a large impact on in vitro to in vivo correlations of intrinsic clearance. Typically, this value is determined experimentally across multiple species in t
Publikováno v:
Biochemical pharmacology. 189
We report here the evaluation of a novel in vitro experimental model, prolonged cultured human hepatocytes (PCHC), as an experimental system to evaluate the potency and duration of effects of oligonucleotide therapeutics. A novel observation was made